Epithalon research

The Epithalon evidence base cited here is 12 sources — 1 clinical, 9 preclinical, 1 review. Its strongest evidence is human — a clinical study, most recently 2024 ("Improving Biological Age, Telomere Length, and Cognition: A Case Study"). Regulatory status: Not FDA-approved.

• Epitalon (Epithalon, sequence Ala-Glu-Asp-Gly) is a synthetic tetrapeptide based on the natural pineal peptide epithalamin, developed by Russian researcher Vladimir Khavinson and studied for over 35 years.
• Its headline mechanism is telomerase activation — reported at extraordinarily low concentrations (10⁻¹⁷–10⁻¹⁵ M) — alongside pineal/melatonin regulation and epigenetic gene-expression effects.
• Most evidence is cell-culture and animal work plus decades of Russian clinical use; it is not FDA-approved. A theoretical telomerase/cancer concern is the key caution.

Epitalon is a four-amino-acid peptide modeled on epithalamin, a regulatory peptide from the pineal gland. It is the most-studied compound in the 'bioregulator' tradition pioneered by Vladimir Khavinson, researched primarily for anti-aging via telomere maintenance and circadian/melatonin support.

It is investigational outside Russia, not FDA-approved, and everything below is research context rather than medical guidance.

Epitalon is a synthetic tetrapeptide — Ala-Glu-Asp-Gly, just 4 amino acids, ~390 Da — making it one of the smallest peptides in research use. It is a synthetic analog of the natural pineal peptide epithalamin.

Epitalon is reported to activate telomerase — the enzyme that maintains the protective telomere caps on chromosomes — at extremely low concentrations, which in cell studies extended replicative lifespan. It also stimulates pineal melatonin production (supporting circadian rhythm), appears to modulate gene expression epigenetically, and has been linked to enhanced antioxidant-enzyme activity. These are largely cell-culture and animal findings; the human anti-aging claim remains inferential.

• Telomerase activation in human fibroblasts (2003): 0.1 µM extended replicative lifespan from 34 to 44+ passages.

Epitalon is not FDA-approved in the US and is sold as a research chemical for laboratory use only, not intended for human consumption. It has a long history of clinical use in Russia.

On the Huberman Lab podcast, Dr. Abud Bakri situated epitalon within Vladimir Khavinson's Soviet 'bioregulator' tradition. The finding he highlighted: epitalon restores melatonin production in aged (but not young) animals and humans, and is tied to a ~15-year nursing-home cohort in which an epitalon-plus-thymalin group showed lower mortality from cardiovascular disease, infection, and cancer.

Two honest caveats he and Dr. Huberman returned to: this is largely Russian-authored data without the replicated, gold-standard Western trials, and the family's 'short peptide assists gene transcription' mechanism is not well established in mainstream molecular biology. Dr. Huberman also mentioned a research interest in epitalon's possible retinal/melanopsin effects from his own former lab focus — an unproven hypothesis, not a clinical claim.

Russian-tradition evidence and expert commentary — promising, but not independently confirmed at Western trial standards.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.